- Home
- CVRX vs IMA Comparison
CVRX vs IMA Comparison
Compare CVRX & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVRX | IMA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.3M | 66.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVRX | IMA |
|---|---|---|
| Price | $1.53 | $4.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $4.58 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 474.0K | 12.3K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,651,000.00 | $800,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $2.20 | $3.94 |
| 52 Week High | $11.30 | $9.10 |
Technical Indicators
Market Signals| Indicator | CVRX | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 23.88 | 30.75 |
| Support Level | N/A | $3.94 |
| Resistance Level | $3.26 | $6.13 |
| Average True Range (ATR) | 0.24 | 0.25 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 2.84 | 1.22 |
Price Performance
Historical ComparisonAbout CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.